Camp - CAMP

Option chain shows key data for Camp4 Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Camp4 Therapeutics.

Camp4 Therapeutics (NASDAQ:CAMP) Stock, Option Chain

Camp4 Therapeutics

CalAmp

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

DocuSign.How-it-Works_2020_thumb_Update

News

Pre-Market Outlook

Movers

Trading Ideas

ASAN

CAMP

DOCU

FOXX

GXAI

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MTEM

ORIS

PGHL

PRFX

RBRK

SATL

SWBI

TARA

VRPX

ZBAO

ZSPC

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

biotech lab ai2

Analyst Color

Biotech

Health Care

Initiation

Analyst Ratings

General

BMRN

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

CAMP4 Analyst Highlights Rare Disease Platform Potential

Intraday Update

Markets

AIRJ

AISP

ARRY

BNED

BWAQ

CLSK

CRBP

CTGO

CURI

CVGW

GWAV

HOTH

KITT

KXIN

LXEH

MIND

MITQ

PIXY

PROK

RAPP

RBOT

SHLS

SIFY

TPET

UBXG

YEXT

Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics Corp

CalAmp Corp

Campbell International Holding Corp

CAMPBELL RES INC by Campbell Resources Inc.

Campbell Resources Inc

Camping World Holdings, Inc. Class A Common Stock

Camping World Holdings Inc

Financing

Press Releases

CalAmp Reaches Comprehensive Agreement to Significantly Reduce Debt, Go Private, and Strengthen Financial Flexibility to Support Innovation Through a Consensual Financial Restructuring

IPOs

CAMP4 Announces Pricing of Initial Public Offering

Earnings

CAMP4 Reports Third Quarter 2024 Financial Results

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMP4 to Participate in Upcoming Investor Conferences

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

KRRO

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

Coherus BioSciences

Coya Therapeutics

Caribou Biosciences

Editas Medicine

Elutia

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Nkarta

OncoCyte

Renovaro

Regulus Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tenaya Therapeutics

Vor Biopharma

XBiotech

Leerink Partners

JP Morgan

Piper Sandler

Goldman Sachs

Craig-Hallum

Comments

Camp4 Therapeutics

Camp4 Therapeutics (CAMP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga